New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:09 EDTCCXIChemoCentryx announces Phase I clinical trial for CCX972 in France
ChemoCentryx announced the initiation of a Phase I clinical trial for CCX872, the company's next-generation of orally administered inhibitors targeting the chemokine receptor known as CCR2. The double-blind, placebo-controlled, single and multiple ascending dose study will evaluate the safety, tolerability and pharmacokinetics of CCX872 in 40 healthy adult subjects. ChemoCentryx' CCR2 program also includes CCX140, the Company's lead CCR2 inhibitor, currently in Phase II clinical trials for the treatment of diabetic nephropathy.
News For CCXI From The Last 14 Days
Check below for free stories on CCXI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CCXI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use